H

ello, everyone, and how are you today? A warm and shiny sun is enveloping the Pharmalot campus this morning, where things have quieted down now that the shortest of short people has left for the schoolhouse and the official mascots are happily snoozing in their recliners. As for us, we are busy foraging for interesting items and, of course, quaffing some cups of stimulation. Feel free to join in. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch …

Gilead Sciences (GILD) won FDA approval of a CAR-T treatment for advanced lymphoma, only the second such medicine approved in the U.S., STAT says. The endorsement validates the $11 billion bet Gilead made recently by buying Kite Pharma, which developed the drug, but also accelerates debate about drug costs, since Gilead will charge $373,000 for a one-time dose for Yescarta. Nonetheless, the approval helps Gilead diversify, which investors have demanded.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.